Robert F. Ozols

Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer et al. · Journal of Clinical Oncology · 2003 · 2.1K citations

Medicine, Gynecology, Oncology +17

Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

William E. Winter, G. Larry Maxwell, Chunqiao Tian et al. · Journal of Clinical Oncology · 2007 · 846 citations · Full text

Medicine, Gynecology, Oncology +15

Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors.

Thomas C. Hamilton, Robert C. Young, Wilma M. McKoy et al. · PubMed · 1983 · 543 citations

Medicine, Cell Biology, Oncology +15

Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion

Thomas C. Hamilton, Margaret A. Winker, Karen G. Louie et al. · Biochemical Pharmacology · 1985 · 540 citations

Medicine, Oncology, Pharmacology +14

Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Brent C. Behrens, Thomas C. Hamilton, Hidetaka Masuda et al. · PubMed · 1987 · 500 citations

Medicine, Oncology, Pharmacology +17